Biomaterial-based vaccine protects against acute myeloid leukemia in mice
Acute myeloid leukemia (AML), a blood cancer that originates in the bone marrow has been treated with chemotherapy for over 40 years. While the treatment does often cause the cancer to go into remission, it does not get rid of all the cancerous cells, so the disease comes back in nearly half of treated patients. Aggressive post-remission treatments, like high-dose chemotherapy or bone marrow transplants, can reduce the chance of recurrence, but many AML patients are not healthy enough to tolerate them.
New research from HSCI presents a promising alternative that has the potential to eliminate AML cells completely. Conducted in mice, the study showed that an injectable, biomaterial-based vaccine, in combination with chemotherapy, led to complete, lasting recovery from, and immunity against, AML. The study was led by HSCI co-director David Scadden and affiliate faculty member David Mooney, and is published in the journal Nature Biomedical Engineering.
This research was supported by the National Institutes of Health, the Cancer Research Institute, and the National Science Foundation.
Source article: Shah, N. J., Najibi, A. J., et al. (2020). A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. Nature Biomedical Engineering. DOI: 10.1038/s41551-019-0503-3